{
  "documents": [
    {
      "id": "cluster_23_doc1",
      "content": "Golden State Insurance confirmed a new process for out-of-network claims requiring pre-approval for rare autoimmune therapies. Dr. Evelyn Marsh at Coastal Immunology Center submitted a claim for patient ID#4582-9173, a 62-year-old with refractory myasthenia gravis, denied on 03/15/2024 due to missing specialist certification. The memo notes exceptional cases may appeal with neurology consult notes and plasma exchange records.",
      "metadata": {
        "format": "insurance_memo"
      }
    },
    {
      "id": "cluster_23_doc2",
      "content": "April 2024 provider bulletin announced expanded coverage for IV immunoglobulin (Gammagard) at Tier 2 copay when prescribed by board-certified immunologists for myasthenia gravis patients. This change applies specifically to members in Southern California regions. Claims must include treatment frequency documentation and physician NPI# 1234567890 for eligibility verification.",
      "metadata": {
        "format": "policy_document"
      }
    },
    {
      "id": "cluster_23_doc3",
      "content": "Patient survey from Dana Point resident Margaret Villegas (DOB 10/22/1961) reported 4-month delay in IVIG authorization despite neurologist Dr. Park's recommendations. Survey notes transportation challenges to Coastal Immunology Center and $12,000 in out-of-pocket costs before policy update. Marked as 'high priority' for grievance resolution.",
      "metadata": {
        "format": "patient_survey"
      }
    },
    {
      "id": "cluster_23_doc4",
      "content": "Clinical trial NCT04560123 at Coastal Immunology Center enrolled 142 participants with refractory neuromuscular conditions. Interim analysis showed 68% reduction in crisis episodes with biweekly Gammagard infusions. Research team: Principal Investigator Dr. R. Srinivasan, Sub-Investigator Dr. E. Marsh. IRB approval granted through 06/2025.",
      "metadata": {
        "format": "research_note"
      }
    }
  ],
  "metadata": {
    "category": "cluster",
    "cluster_id": "cluster_23",
    "cluster_risk": "HIGH",
    "content_summary": "A patient's journey through autoimmune treatment authorization challenges, policy changes for IVIG coverage, and participation in a clinical trial at Coastal Immunology Center.",
    "person": {
      "entities": [
        [
          "Margaret Villegas",
          "NAME"
        ],
        [
          "10/22/1961",
          "BIRTHDATE"
        ],
        [
          "4582-9173",
          "PATIENT_ID"
        ],
        [
          "refractory myasthenia gravis",
          "MEDICAL_CONDITION"
        ],
        [
          "62-year-old",
          "AGE"
        ],
        [
          "$12,000",
          "UNIQUE_FACT"
        ],
        [
          "4-month delay",
          "UNIQUE_FACT"
        ],
        [
          "03/15/2024",
          "EVENT_DATE"
        ],
        [
          "denied",
          "EVENT"
        ],
        [
          "Coastal Immunology Center",
          "PROVIDER"
        ],
        [
          "Dr. Evelyn Marsh",
          "PROVIDER"
        ],
        [
          "Dr. Park",
          "PROVIDER"
        ],
        [
          "Gammagard",
          "TREATMENT"
        ],
        [
          "IVIG authorization",
          "EVENT"
        ],
        [
          "Dana Point",
          "LOCATION"
        ]
      ]
    },
    "questions": [
      {
        "q": "What was the reason for the initial denial of IVIG treatment for patient ID#4582-9173 at Coastal Immunology Center?",
        "a": "Missing specialist certification and neurology consult notes.",
        "sources": [
          "cluster_23_doc1"
        ],
        "type": "specific"
      },
      {
        "q": "What April 2024 policy change affected Southern California patients requiring Gammagard infusions?",
        "a": "Expanded Tier 2 copay coverage with immunologist certification.",
        "sources": [
          "cluster_23_doc2"
        ],
        "type": "general"
      },
      {
        "q": "Which two providers at Coastal Immunology Center are associated with patient Margaret Villegas's care and the clinical trial?",
        "a": "Dr. Evelyn Marsh and Dr. R. Srinivasan.",
        "sources": [
          "cluster_23_doc1",
          "cluster_23_doc4"
        ],
        "type": "specific"
      },
      {
        "q": "What policy change and financial/logistical challenges were reported in Dana Point patient surveys related to autoimmune therapies?",
        "a": "Expanded Tier 2 copay coverage and $12,000 out-of-pocket costs, plus transportation difficulties.",
        "sources": [
          "cluster_23_doc2",
          "cluster_23_doc3"
        ],
        "type": "general"
      }
    ]
  }
}